Use the hyperlinks, where available to access additional clinical trial information.
Three versus five years of adjuvant Imatinib as treatment for patients with operable gastrointestinal stromal tumour (GIST) with a high risk for recurrence: SSGXXII: A Randomised phase III study
Australasian Gastro-Intestinal Trials Group (AGITG)
Other Non-Commercial Sponsor
University of Sydney
To be eligible for this study you must be at least 18 years old, have been diagnosed with gastrointestinal stromal tumour (GIST), and have been treated with adjuvant imatinib for 3 years after previously having surgery. Eligible participants will be enrolled and randomly assigned to either continue to receive imatinib oral tablets (400mg/day) for 2 years, or to receive no further imatinib treatment.